全文获取类型
收费全文 | 2512篇 |
免费 | 231篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 112篇 |
妇产科学 | 40篇 |
基础医学 | 280篇 |
口腔科学 | 123篇 |
临床医学 | 261篇 |
内科学 | 793篇 |
皮肤病学 | 29篇 |
神经病学 | 116篇 |
特种医学 | 199篇 |
外科学 | 319篇 |
综合类 | 53篇 |
预防医学 | 139篇 |
眼科学 | 10篇 |
药学 | 139篇 |
中国医学 | 24篇 |
肿瘤学 | 84篇 |
出版年
2023年 | 22篇 |
2022年 | 28篇 |
2021年 | 62篇 |
2020年 | 38篇 |
2019年 | 64篇 |
2018年 | 82篇 |
2017年 | 81篇 |
2016年 | 79篇 |
2015年 | 90篇 |
2014年 | 99篇 |
2013年 | 131篇 |
2012年 | 138篇 |
2011年 | 145篇 |
2010年 | 121篇 |
2009年 | 119篇 |
2008年 | 133篇 |
2007年 | 136篇 |
2006年 | 95篇 |
2005年 | 104篇 |
2004年 | 104篇 |
2003年 | 82篇 |
2002年 | 52篇 |
2001年 | 58篇 |
2000年 | 45篇 |
1999年 | 16篇 |
1998年 | 67篇 |
1997年 | 60篇 |
1996年 | 57篇 |
1995年 | 56篇 |
1994年 | 31篇 |
1993年 | 43篇 |
1992年 | 23篇 |
1991年 | 28篇 |
1990年 | 25篇 |
1989年 | 21篇 |
1988年 | 31篇 |
1987年 | 25篇 |
1986年 | 19篇 |
1985年 | 13篇 |
1984年 | 19篇 |
1983年 | 18篇 |
1982年 | 6篇 |
1981年 | 16篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 7篇 |
1977年 | 15篇 |
1976年 | 11篇 |
1975年 | 5篇 |
1970年 | 6篇 |
排序方式: 共有2756条查询结果,搜索用时 15 毫秒
81.
82.
Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody 总被引:1,自引:1,他引:1
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC 《Blood》1994,83(6):1632-1639
Antigenic modulation is one of many factors determining the effectiveness of monoclonal antibody (MoAb)-mediated therapy. To select the isotype of a CD19 MoAb most suitable for radioimmunotherapy of patients with B-cell malignancies, we studied the influence of MoAb isotype on modulation, after binding of the MoAb to different cell-line cells. The CD19-IgG1 MoAb was found to induce modulation of CD19 antigens on Daudi cell line cells more rapidly than did its IgG2a switch variant. We provide evidence that this difference in modulation rate is caused by the expression of Fc gamma receptor II (Fc gamma RII) on these cells. Experiments aimed at elucidating the mechanism of Fc gamma RII involvement in modulation induction by CD19-IgG1 showed that Fc gamma RII did not comodulate with CD19 MoAbs. However, cocrosslinking of CD19 and Fc gamma RII with CD19-IgG1 MoAb resulted in enhanced calcium mobilization in Daudi cells. This increased signal induction accompanies the enhanced capping and subsequent modulation of CD19 antigens. Because Fc gamma RII is expressed in varying densities on malignant B cells in all differentiation stages, our results have implications for the MoAb isotype most suitable for use in MoAb-based therapy of patients with B-cell malignancies. 相似文献
83.
Aliza Hussain Wensheng Sun Anita Deswal James A. de Lemos John W. McEvoy Ron C. Hoogeveen Kunihiro Matsushita David Aguilar Biykem Bozkurt Salim S. Virani Amil M. Shah Elizabeth Selvin Chiadi Ndumule Christie M. Ballantyne Vijay Nambi 《Journal of the American College of Cardiology》2021,77(5):559-571
BackgroundAlthough intensive blood pressure reduction has cardiovascular benefits, the absolute benefit is greater in those at higher cardiovascular disease (CVD) risk.ObjectivesThis study examined whether N-terminal pro–B-type natriuretic peptide (NT-proBNP) helps identify subjects at higher risk for CVD events across systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse pressure (PP) categories.MethodsParticipants from the ARIC (Atherosclerosis Risk In Communities) study visit 4 (1996 to 98) were grouped according to SBP, DBP, or PP categories and further stratified by NT-proBNP categories. Cox regression models were used to estimate hazard ratios for incident CVD (coronary heart disease, ischemic stroke, or heart failure hospitalization) and mortality across combined NT-proBNP and/or BP categories, adjusting for CVD risk factors.ResultsThere were 9,309 participants (age: 62.6 ± 5.6 years; 58.3% women) with 2,416 CVD events over a median follow-up of 16.7 years. Within each SBP, DBP, or PP category, a higher category of NT-proBNP (100 to <300 or 300 pg/ml, compared with NT-proBNP <100 pg/ml) was associated with a graded increased risk for CVD events and mortality. Participants with SBP 130 to 139 mm Hg but NT-proBNP ≥300 pg/ml had a hazards ratio of 3.4 for CVD (95% confidence interval: 2.44 to 4.77) compared with a NT-proBNP of <100 pg/ml and SBP of 140 to 149 mm Hg.ConclusionsElevated NT-proBNP is independently associated with CVD and mortality across SBP, DBP, and PP categories and helps identify subjects at the highest risk. Participants with stage 1 hypertension but elevated NT-proBNP had greater cardiovascular risk compared with those with stage 2 SBP but lower NT-proBNP. Future studies are needed to evaluate use of biomarker-based strategies for CVD risk assessment to assist with initiation or intensification of BP treatment. 相似文献
84.
A sensitive and precise radioreceptor assay for determining plasma levels of human factor VIII/von Willebrand's factor (FVIII/vWF) has been developed by taking advantage of the FVIII/vWF receptor sites on human platelets. Paraformaldehyde-fixed platelets, which were processed and then stored, retained FVIII/vWF binding activity and therefore could be used as a convenient source of receptors. The human plasma samples to be tested were initially filtered on 4% agarose columns to concentrate the FVIII/vWF protein in the void volume and to remove the factor(s) that interferes with the assay. The percent recovery of FVIII/vWF in the pooled eluent was measured by the recovery of added trace 125I-FVIII/vWF. The coefficients of intra- and interassay variation were 6% and 10%, respectively. The plasma FVIII/vWF concentrations determined by the assay for pooled normal plasma, hemophilia A plasma, and plasmas from two patients with von Willebrand's disease were 16.3 +/- 0.5, 52.6 +/- 1.5, 6.8 +/- 0.8, and 3.2 +/- 0.2 microgram/ml, respectively. The range of plasma FVIII/vWF concentrations varied between 8.3 microgram/ml and 24.9 microgram/ml for 10 normal adults. The plasma FVIII/vWF concentrations determined by the radioreceptor assay correlated well with levels measured by the ristocetin-induced platelet aggregation method, thus demonstrating the functional relevancy of the radioreceptor assay for plasma FVIII/vWF. 相似文献
85.
Fredric Assis Oliveira Pedro A. Lemos 《Catheterization and cardiovascular interventions》2020,96(2):422-423
- Chronic thrombocytopenia is frequent in patients undergoing TAVR in the real world.
- Chronic thrombocytopenia is associated with worse in‐hospital outcomes after TAVR.
- Future research is necessary to establish a better way of conducting and monitoring these patients.
86.
87.
Lemos PA Arampatzis CA Hoye A Daemen J Ong AT Saia F van der Giessen WJ McFadden EP Sianos G Smits PC de Feyter P Hofma SH van Domburg RT Serruys PW 《The American journal of cardiology》2005,95(2):167-172
Renal impairment is an important predictor of mortality after percutaneous coronary intervention and may increase the restenosis rate. However, the relation between restenosis and the risk of death in patients who have renal impairment remains unclear. We evaluated the incidences of repeat revascularization and mortality in patients who had renal impairment and those who did not and who received sirolimus-eluting stents or bare stents. A total of 1,080 consecutive patients treated for 1 year had available data to calculate baseline creatinine clearance. Patients received bare stents (first 6 months, n = 543) or sirolimus-eluting stents (last 6 months, n = 537) and were grouped according to the presence or absence of renal impairment (creatinine clearance <60 ml/min). Patients who had renal impairment had a higher mortality rate at 1 year (7.6% vs 2.5%, hazard ratio 3.14, 95% confidence interval 1.68 to 5.88, p <0.01), with no differences in mortality between patients who received bare stents and those who received sirolimus-eluting stents (hazard ratio 0.91, 95% confidence interval 0.49 to 1.68, p = 0.8). The incidence of target vessel revascularization decreased significantly in patients who were treated with sirolimus-eluting stents and did not have renal impairment (hazard ratio 0.59, 95% confidence interval 0.39 to 0.90, p = 0.01) and in those who had decreased renal function (hazard ratio 0.37, 95% confidence interval 0.15 to 0.90, p = 0.03). Thus, sirolimus-eluting stents compared with conventional stents decreased clinical restenosis in patients who had renal impairment. However, this benefit was not paralleled by a decrease in the risk of death in this population. It seems unlikely that restenosis could be a contributing factor that influenced the increased mortality of patients who had impaired renal function. 相似文献
88.
Abdullah SM Khera A Das SR Stanek HG Canham RM Chung AK Morrow DA Drazner MH McGuire DK de Lemos JA 《The American journal of cardiology》2005,96(9):1284-1289
Elevated plasma levels of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-pro-BNP) are seen in the setting of cardiac ischemia and are associated with adverse outcomes in patients with coronary artery disease. The mechanisms leading to natriuretic peptide elevation in patients with coronary artery disease, including the contribution of coronary atherosclerosis itself, have not been fully elucidated. Measurement of NT-pro-BNP, electron beam computed tomography, and cardiac magnetic resonance imaging were performed in 2,445 subjects from the Dallas Heart Study who were free of heart failure and renal insufficiency. Electron beam computed tomography-determined coronary artery calcium scores were categorized as none (<10), mild (> or =10 to <100), moderate (> or =100 to <400), and severe (> or =400). NT-pro-BNP levels increased significantly across increasing coronary artery calcium score categories (p <0.0001 for trend). In multivariate models adjusted for age, gender, race, body mass index, hypertension, history of myocardial infarction, angina, angiotensin-converting enzyme inhibitor use, beta-blocker use, left ventricular (LV) ejection fraction, and LV mass, higher coronary artery calcium scores remained independently associated with higher log NT-pro-BNP levels (p = 0.03). This association persisted in similar models excluding patients with low LV ejection fractions, LV hypertrophy, angina pectoris, and a history of myocardial infarction. In conclusion, these findings support the hypothesis that coronary atherosclerosis may directly influence the activation of the cardiac neurohormonal system. 相似文献
89.
Long‐term efficacy of a 0.07% cetylpyridinium chloride mouth rinse in relation to plaque and gingivitis: a 6‐month randomized,vehicle‐controlled clinical trial
下载免费PDF全文
![点击此处可从《International journal of dental hygiene》网站下载免费的PDF全文](/ch/ext_images/free.gif)
90.